文献速递眼底病与葡萄膜炎

不同分期最佳卵黄样黄斑营养不良的频域光学相干断层扫描特征

SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY FEATURES IN DIFFERENT STAGES OF BEST VITELLIFORM MACULAR DYSTROPHY.
PubMed 文献 · Retina · 2018-01-01

该前瞻性横断面研究纳入47例患者94眼,采用SD-OCT评估不同分期最佳卵黄样黄斑营养不良的特征。结果显示2至4期外层视网膜层破坏常见(86%-100%),5期以缺失为主(71%-86%);卵黄样物质在2、3期100%存在,4期93%,5期43%。存在卵黄样物质者BCVA优于无者(0.35 logMAR vs 0.80±0.36 logMAR),其缺失与BCVA≤0.5 logMAR相关。

要点

  • 2至4期外层视网膜层破坏常见(86%-100%),5期以缺失为主(71%-86%)
  • 卵黄样物质在2、3期100%存在,4期93%,5期43%
  • 存在卵黄样物质者BCVA优于无者(0.35 vs 0.80±0.36 logMAR)

核心结论

  • SD-OCT评估主要提示2至4期外层视网膜层破坏,卵黄样物质也可见于更晚期临床阶段。
  • 以卵黄样物质持续存在为特征的眼BCVA更好。
  • 未来需基于纵向随访的研究将SD-OCT改变与功能反应相关联,以确定用于预后和治疗目的的SD-OCT指标。

研究设计与样本

  • 前瞻性横断面研究,纳入47例患者94眼。
  • 所有患者接受完整眼科检查,包括ETDRS视力表最佳矫正视力、生物显微镜检查和SD-OCT。

主要发现

  • 外层视网膜层(外界膜、椭圆体带和视网膜色素上皮)在2至4期更常破坏(范围86%-100%),其缺失更典型见于5期(71%-86%)。
  • 卵黄样物质在2期和3期100%存在,4期93%,5期43%。
  • 有卵黄样物质眼BCVA为0.35 logMAR,无卵黄样物质眼为0.80±0.36 logMAR(分别约20/45和20/125 Snellen等效)(t=3.726,P<0.05)。
  • 卵黄样物质缺失与BCVA≤0.5 logMAR(约20/63 Snellen等效)相关(P<0.05)。
  • 视网膜下液在3期和4期更常见(分别为72.7%和75%),高于2期和5期(P=0.004);有视网膜下液眼与BCVA≤0.2 logMAR(约20/32 Snellen等效)显著相关(P=0.04)。

局限性

  • 未来需基于纵向随访的研究将SD-OCT改变与功能反应相关联,以确定用于预后和治疗目的的SD-OCT指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To provide a systematic classification of findings regarding the different stages of vitelliform macular dystrophy on spectral domain optical coherence tomography (SD-OCT). METHODS: Ninety-four eyes of 47 patients were recruited in a prospective cross-sectional study. All patients underwent a complete ophthalmologic examination, including best-corrected visual acuity using Early Treatment Diabetic Retinopathy Study (ETDRS) charts, biomicroscopy, and SD-OCT. The findings assessed included vitelliform material, neurosensory detachment, status of external limiting membrane, ellipsoid zone and retinal pigment epithelium, choroidal excavation, foveal cavitation, choroidal neovascularization, vitreomacular traction, and macular hole. The primary outcome measure was the identification of SD-OCT findings in each vitelliform macular dystrophy stage. Secondary outcomes included the correlations between SD-OCT features and visual acuity changes. RESULTS: The outer retinal layers (external limiting membrane, ellipsoid zone, and retinal pigment epithelium) were found to be more commonly disrupted in Stages 2 to 4 (range: 86%-100%), whereas their absence was more typical of Stage 5 (71%-86%). Vitelliform material was found in 100% of Stages 2 and 3, 93% of Stage 4, and interestingly in 43% of Stage 5. Eyes characterized by vitelliform material showed a greater correlation with higher best-corrected visual acuity than eyes without it (0.35 logarithm of the minimum angle of resolution vs. 0.80 ± 0.36 logarithm of the minimum angle of resolution, approximately 20/45 and 20/125 Snellen equivalent, respectively) (t = 3.726, P < 0.05). Moreover, its absence was associated with a best-corrected visual acuity of 0.5 logarithm of the minimum angle of resolution or worse (approximately 20/63 Snellen equivalent; P < 0.05). Subretinal fluid was more common in Stages 3 and 4 (72.7% and 75%, respectively) than Stages 2 and 5 (P = 0.004). Eyes with subretinal fluid were significantly associated with a visual acuity of 0.2 logarithm of the minimum angle of resolution or worse (approximately 20/32 Snellen equivalent; P = 0.04). CONCLUSION: Spectral domain optical coherence tomography assessment primarily indicates an outer retinal layer disruption in Stages 2 to 4, along with the presence of vitelliform material extending into the more advanced clinical stages too. Eyes characterized by the persistence of vitelliform material show better best-corrected visual acuity. Future investigations based on a longitudinal follow-up are warranted to correlate SD-OCT modifications with functional responses to identify SD-OCT indicators for prognostic and therapeutic purposes.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Battaglia Parodi M, Iacono P, Romano F, et al. SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY FEATURES IN DIFFERENT STAGES OF BEST VITELLIFORM MACULAR DYSTROPHY. Retina. 2018. PMID: 28376040. doi:10.1097/IAE.0000000000001634

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。